arrow
A

Atsushi Takai

the japanese society of gastroenterology and the japan society of hepatology
H指数:25
被引数:2,106

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Evidence-Based Clinical Practice Guidelines for Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) 2026

代谢功能障碍相关脂肪性肝病(MASLD)2026年循证临床实践指南

2026-05-120
OAAI
Lenvatinib Versus Atezolizumab Plus Bevacizumab as First-Line Treatment for Advanced Hepatocellular Carcinoma With a CRAFITY Score of 2: A Multi-Center Retrospective Study

仑伐替尼与阿替利珠单抗联合贝伐珠单抗作为CRAFITY评分为2分的晚期肝细胞癌的一线治疗:一项多中心回顾性研究

2025-09-130
PRE
CRAFITY score as a predictive marker for refractoriness to atezolizumab plus bevacizumab therapy in hepatocellular carcinoma: a multicenter retrospective study (oct, 10.1007/s00535-024-02150-7, 2024)
2024-10-210
OAAI
CRAFITY score as a predictive marker for refractoriness to atezolizumab plus bevacizumab therapy in hepatocellular carcinoma: a multicenter retrospective study
2024-09-182
OAAI
RECAM-J 2023-Validation and development of the Japanese version of RECAM for the diagnosis of drug-induced liver injury

Recam-j 2023-用于诊断药物性肝损伤的日文版RECAM的验证和开发

2024-04-205
PRE
Integrated analyses of the genetic and clinicopathological features of cholangiolocarcinoma: cholangiolocarcinoma may be characterized by mismatch-repair deficiency
2024-02-161
PRE